Search Results | Blood | American Society of Hematology

1-20 of 2578

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Retinoic acid–responsive CD8 effector T cells are selectively increased in IL-23–rich tissue in gastrointestinal GVHD

Jennifer A. Ball, Andrew Clear, James Aries, Sarah Charrot, Caroline Besley, Matt Mee, Andrew Stagg, James O. Lindsay, Jamie Cavenagh, Maria Calaminci, John G. Gribben, Jeff Davies

Blood (2021) 137 (5): 702–717.

DOI: https://doi.org/10.1182/blood.2020005170

Published: 2021

Includes: Supplemental data

Journal Articles

The different flavors and splices of MCL

Oliver Weigert

Blood (2020) 136 (5): 526–527.

DOI: https://doi.org/10.1182/blood.2020005591

Published: 2020

Journal Articles

Reproducing the molecular subclassification of peripheral T-cell lymphoma–NOS by immunohistochemistry

Blood (2019) 134 (24): 2159–2170.

DOI: https://doi.org/10.1182/blood.2019000779

Published: 2019

Includes: Supplemental data

Journal Articles

Development of a Human in Vitro Cell Model for Haemophilia a

Rosa Toenges, MD, Nadin Hodroj, Nina Kurrle, PhD, Wolfgang Miesbach, MD PhD, Frank Schnuetgen, PhD, Hubert Serve, MD

Blood (2019) 134 (Supplement_1): 3634.

DOI: https://doi.org/10.1182/blood-2019-121908

Published: 2019

Journal Articles

Microglia-like Cells Derived from Hematopoietic Stem and Progenitor Cells Are a Model System to Investigate Chronic Pain in Sickle Cell Disease

Yankai Zhang, PhD, Celeste K. Kanne, BA, Jennifer N. Tran, DO, Michael J. Lacagnina, PhD, Peter M. Grace, PhD, Vivien A. Sheehan, MD PhD

Blood (2019) 134 (Supplement_1): 3575.

DOI: https://doi.org/10.1182/blood-2019-128921

Published: 2019

Journal Articles

A Novel Chemical Compound Inhibiting Hematopoietic Cell Kinase (iHCK) Has a Synergic Effect with Azacytidine (Aza) or Cytarabine (Ara-C) for Acute Myeloid Leukemia Treatment

Fernanda Marconi Roversi, Maura Lima Pereira Bueno, undergraduate, Cristiane Okuda Torello, PhD, Fernanda I Della Via, MSc, Renata Giardini Rosa, PhD, Juares Ednaldo Romero Bianco, PhD, Adriana Silva Santos Duarte, PhD, Eduardo M Rego, MD PhD, Alessio Molinari, Maurizio Botta, Sara T Olalla Saad, PhD

Blood (2019) 134 (Supplement_1): 4650.

DOI: https://doi.org/10.1182/blood-2019-128959

Published: 2019

Journal Articles

Fas Mutations in Non-Hodgkin's Lymphoma (NHL): Implications for Disease Progression and Therapeutic Resistance

Ryan N Rys, BSc, BA, Maanasa Venkataraman, MSc, Jibin Zeng, MSc, Koren Kathleen Mann, PhD, Nathalie Johnson, MD

Blood (2019) 134 (Supplement_1): 1520.

DOI: https://doi.org/10.1182/blood-2019-130602

Published: 2019

Journal Articles

Targeting B-Cell Maturation Antigen (BCMA) with CC-93269, a 2+1 T Cell Engager, Elicits Significant Apoptosis in Diffuse Large B-Cell Lymphoma Preclinical Models

Patrick R. Hagner, PhD, Michelle Waldman, MS, Falon D. Gray, DVM, DACVP, Renee Yura, PhD, Sarah Hersey, MS, MBA, Henry Chan, PhD, Mingjun Zhang, PhD, Isaac Boss, Anita K Gandhi

Blood (2019) 134 (Supplement_1): 1580.

DOI: https://doi.org/10.1182/blood-2019-126115

Published: 2019

Journal Articles

Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories

Hagop M. Kantarjian, MD, Wendy Stock, MD, Ryan D. Cassaday, MD, Daniel J. DeAngelo, MD PhD, Elias Jabbour, MD, Susan M. O'Brien, MD, Matthias Stelljes, MD, Tao Wang, M. Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, MD, Erik R. Vandendries, MD PhD, Alexander Neuhof, MD, A. Douglas Laird, PhD, Anjali S. Advani, MD

Blood (2019) 134 (Supplement_1): 1344.

DOI: https://doi.org/10.1182/blood-2019-122097

Published: 2019

Journal Articles

Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma

Blood (2019) 134 (Supplement_1): 1585.

DOI: https://doi.org/10.1182/blood-2019-123933

Published: 2019

Journal Articles

MYC Expression in Systemic Anaplastic Large Cell Lymphoma: Clinicopathologic and Prognostic Features of 70 Patients

Kirill A. Lyapichev, MD, L. Jeffrey Medeiros, MD, Shaoying Li, MD, C. Cameron Yin, MD PhD, Guilin Tang, MD, M. James You, MD PhD, Sergej Konoplev, Swaminathan P. Iyer, MD, Carlos E. Bueso-Ramos, MD PhD, Roberto N. Miranda, MD, Jie Xu

Blood (2019) 134 (Supplement_1): 1560.

DOI: https://doi.org/10.1182/blood-2019-124556

Published: 2019

Journal Articles

Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study

Blood (2019) 134 (Supplement_1): 1589.

DOI: https://doi.org/10.1182/blood-2019-123637

Published: 2019

Journal Articles

Targeted Next Generation Sequencing Reveals Molecular Heterogeneity in Non-CLL Clonal B-Cell Lymphocytosis

Irene Defrancesco, Silvia Zibellini, Emanuela Boveri, Marco Frigeni, Virginia Valeria Ferretti, Ettore Rizzo, Francesca Capuano, Arturo Bonometti, Chiara Candido, Sara Rattotti, Elena Flospergher, Fabio Bergamini, Caterina Zerbi, Marco Paulli, Marzia Varettoni, Luca Arcaini

Blood (2019) 134 (Supplement_1): 1502.

DOI: https://doi.org/10.1182/blood-2019-130233

Published: 2019

Journal Articles

Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?

Blood (2019) 134 (Supplement_1): 1532.

DOI: https://doi.org/10.1182/blood-2019-131442

Published: 2019

Journal Articles

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

Jose C Villasboas, MD, Craig B. Reeder, MD, Han W. Tun, MD, Nancy L Bartlett, MD, Elad Sharon, MD MPH, Betsy Laplant, MS, Alex A Adjei, MD PhD, Justin Kline, MD, Francisco J. Hernandez-Ilizaliturri, MD, Farrukh T. Awan, MD, Sumana Devata, MD, Aleksandr Lazaryan, MDPhDMPH, Lawrence E Morris, MD, Stephen M Ansell, MD PhD, Catherine Diefenbach, MD

Blood (2019) 134 (Supplement_1): 1591.

DOI: https://doi.org/10.1182/blood-2019-130449

Published: 2019

Journal Articles

A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)

Sarit Assouline, MD, Amitkumar Mehta, MD, Paolo F Caimi, MD, Bingxia Wang, PhD, Chirag Patel, Mi-Sook Kim, Dennis Huszar, Allison J Berger, PhD, Sharon Friedlander, Alejandro Gomez-Pinillos, Igor Proscurshim

Blood (2019) 134 (Supplement_1): 1593.

DOI: https://doi.org/10.1182/blood-2019-128773

Published: 2019

Journal Articles

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

Dai Chihara, MD PhD, Evgeny Arons, PhD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Hao-Wei Wang, MD PhD, Hong Zhou, Mark Raffeld, MD, Liqiang Xi, MD, Seth M. Steinberg, PhD, Julie Feurtado, RN, Lacey James-Echenique, CRNP, Wyndham Wilson, MD, Raul C. Braylan, MD, Katherine R. Calvo, MD PhD, Irina Maric, MD MSci, Alina Dulau-Florea, MD, Robert J. Kreitman, MD

Blood (2019) 134 (Supplement_1): 1536.

DOI: https://doi.org/10.1182/blood-2019-124515

Published: 2019

Journal Articles

A Multicenter, Open-Label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105

Carlyn Rose Tan, MD, Stefan K. Barta, MD MRCP, MS, Shelly Y. Lensing, Ariela Noy, MD

Blood (2019) 134 (Supplement_1): 1595.

DOI: https://doi.org/10.1182/blood-2019-129702

Published: 2019

Journal Articles

Epigenetic Modulation of CD48 By NPM-ALK Promotes Immune Evasion in ALK+ ALCL

Rui Wu, MD PhD, Elena Ivan, MD, Anagh Anant Sahasrabuddhe, PhDMSc,BSc, Timothy Shaw, PhD, Charles G. Mullighan, MBBS, MD, Vasiliki Leventaki, Kojo S. J. Elenitoba-Johnson, MD, Megan S. Lim, MD PhD

Blood (2019) 134 (Supplement_1): 1510.

DOI: https://doi.org/10.1182/blood-2019-127453

Published: 2019

Journal Articles

Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations

Xiaoxian Zhao, PhD, Bartlomiej Przychodzen, Juraj Bodo, PhD, Lisa Durkin, Daniel Lindner, MD PhD, Neetha Parameswaran, PhD, Michael Clemente, MS, Sarah L. Ondrejka, DO, Jaroslaw P. Maciejewski, MD PhD, Deepa Jagadeesh, MDMPH, Eric D. Hsi, MD

Blood (2019) 134 (Supplement_1): 1572.

DOI: https://doi.org/10.1182/blood-2019-129131

Published: 2019

2 3 4 5

NARROW

Retinoic acid–responsive CD8 effector T cells are selectively increased in IL-23–rich tissue in gastrointestinal GVHD

The different flavors and splices of MCL

Reproducing the molecular subclassification of peripheral T-cell lymphoma–NOS by immunohistochemistry

Development of a Human in Vitro Cell Model for Haemophilia a

Microglia-like Cells Derived from Hematopoietic Stem and Progenitor Cells Are a Model System to Investigate Chronic Pain in Sickle Cell Disease

A Novel Chemical Compound Inhibiting Hematopoietic Cell Kinase (iHCK) Has a Synergic Effect with Azacytidine (Aza) or Cytarabine (Ara-C) for Acute Myeloid Leukemia Treatment

Fas Mutations in Non-Hodgkin's Lymphoma (NHL): Implications for Disease Progression and Therapeutic Resistance

Targeting B-Cell Maturation Antigen (BCMA) with CC-93269, a 2+1 T Cell Engager, Elicits Significant Apoptosis in Diffuse Large B-Cell Lymphoma Preclinical Models

Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories

Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma

MYC Expression in Systemic Anaplastic Large Cell Lymphoma: Clinicopathologic and Prognostic Features of 70 Patients

Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study

Targeted Next Generation Sequencing Reveals Molecular Heterogeneity in Non-CLL Clonal B-Cell Lymphocytosis

Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

A Multicenter, Open-Label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105

Epigenetic Modulation of CD48 By NPM-ALK Promotes Immune Evasion in ALK+ ALCL

Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only